GLP1R and heart failure: In a systematic review and meta-analysis of seven large cardiovascular outcome trials (involving a total of ~56,000 participants), Kristensen et al. [50] showed that GLP-1 RAs significantly reduced major adverse cardiovascular events by 12%, all-cause mortality by 12%, hospital admission for heart failure by ~10%, and chronic kidney disease by 17% in individuals with T2DM.